AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

Phase 2

Completed

Conditions: Chronic Kidney Disease
Heart Failure

Interventions: Drug: AZD9977
Drug: Dapagliflozin

First Posted Date: 2020-10-20

Last Posted Date: 2024-11-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 153

Registration Number: NCT04595370

Locations: 🇺🇦
Research Site, Kyiv, Ukraine

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Phase 3

Active, not recruiting

Conditions: Gastrointestinal Neoplasms
Esophagogastric Junction

Interventions: Drug: Durvalumab
Drug: FLOT chemotherapy

First Posted Date: 2020-10-19

Last Posted Date: 2025-04-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 958

Registration Number: NCT04592913

Locations: 🇬🇧
Research Site, Surrey, United Kingdom

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

Phase 1

Completed

Conditions: Cardiovascular Disease

Interventions: Drug: AZD3366
Drug: Placebo
Drug: Ticagrelor
Drug: acetylsalicylic acid (ASA)

First Posted Date: 2020-10-19

Last Posted Date: 2023-12-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 103

Registration Number: NCT04588727

Locations: 🇺🇸
Research Site, Glendale, California, United States

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Phase 1

Active, not recruiting

Conditions: Neurofibroma Plexiform
Neurofibromatosis 1

Interventions: Drug: Selumetinib

First Posted Date: 2020-10-19

Last Posted Date: 2025-05-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 32

Registration Number: NCT04590235

Locations: 🇨🇳
Research Site, Shanghai, China

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

Phase 3

Active, not recruiting

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Monalizumab
Other: Placebo
Drug: Cetuximab

First Posted Date: 2020-10-19

Last Posted Date: 2025-05-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 370

Registration Number: NCT04590963

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

A Study of Adavosertib as Treatment for Uterine Serous Carcinoma

Phase 2

Completed

Conditions: Uterine Serous Carcinoma

Interventions: Drug: Adavosertib

First Posted Date: 2020-10-19

Last Posted Date: 2023-08-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 109

Registration Number: NCT04590248

Locations: 🇪🇸
Research Site, Pozuelo de Alarcón, Spain

A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer

Phase 2

Completed

Conditions: HER2-negative Breast Cancer

Interventions: Drug: AZD9833

First Posted Date: 2020-10-19

Last Posted Date: 2025-01-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 135

Registration Number: NCT04588298

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Biological: MEDI3506

First Posted Date: 2020-09-30

Last Posted Date: 2024-01-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 250

Registration Number: NCT04570657

Locations: 🇬🇧
Research Site, London, United Kingdom

Study of AZD1222 for the Prevention of COVID-19 in Japan

Phase 1

Completed

Conditions: COVID-19

Interventions: Drug: 0.9% (w/v) saline
Drug: AZD1222

First Posted Date: 2020-09-29

Last Posted Date: 2024-03-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 256

Registration Number: NCT04568031

Locations: 🇯🇵
Research Site, Toshima-ku, Japan

Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice

Completed

Conditions: Myocardial Infarction (MI)

First Posted Date: 2020-09-29

Last Posted Date: 2022-04-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 7035

Registration Number: NCT04568083

Locations: 🇬🇧
Research Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy